- Home >
- Clinicals Trials >
- EMBER-3 (J2J-OX-JZLC)
EMBER-3 (J2J-OX-JZLC)
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
- Open at Paris since : 15/04/2022
- Open at Saint-Cloud since : 03/03/2022
- Target : Adult
- Phase : Phase III
Trial description
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.
Url of the trial